The current market price of Nippon India NIFTY Pharma ETF Growth Plan is ₹26.47. ETF prices fluctuate during market hours based on demand, supply, and movements in the underlying index or assets.

Nippon India NIFTY Pharma ETF Growth Plan, managed by Nippon Life India Asset Management Limited, is an Equity - ETF employing a Passive approach with an explicit objective to track the Nifty Pharma TRI constituents precisely. The fund pursues full‑replication passive strategy aligned to the Nifty Pharma TRI benchmark, seeking minimal tracking mismatch and reporting a low tracking error of 0.0% which underscores tight benchmark adherence. Portfolio concentration is pronounced: Pharmaceuticals & Biotechnology represent 99.9% of assets and the top five names — Sun Pharmaceutical (21.3%), Divi's (9.7%), Cipla (9.4%), Dr. Reddy's (9.4%), Lupin (6.6%) — total 56.3%. Performance disclosure shows 1Y: +15.3%, reflecting sector-driven returns within the pharmaceutical complex while multi‑year CAGR figures are not provided in the available dataset for longer-term comparison. Operationally the ETF held AUM of ₹1007.5 Cr as on Jan 2026 with monthly average ₹1007.0 Cr, carries an expense ratio of 0.2%, and is managed by Jitendra Tolani since Feb 2025.

Nippon India NIFTY Pharma ETF Growth Plan is designed to track Nifty Pharma TRI, allowing investors to gain exposure to its underlying securities through a single investment.

The expense ratio of Nippon India NIFTY Pharma ETF Growth Plan is 0.21%. This represents the annual fee charged by the fund house for managing the ETF and is deducted from the fund’s assets.

The Assets Under Management (AUM) of Nippon India NIFTY Pharma ETF Growth Plan is approximately ₹1,007.47. AUM reflects the total market value of assets managed by the ETF and is often used as an indicator of fund size and liquidity.

Nippon India NIFTY Pharma ETF Growth Plan is classified under the Very High risk category. The risk level depends on the volatility of the underlying index, market conditions, and asset composition of the ETF.

The tracking error of Nippon India NIFTY Pharma ETF Growth Plan is 0.02%. Tracking error measures how closely the ETF’s performance matches its benchmark index over time.

Nippon India NIFTY Pharma ETF Growth Plan has a dividend yield of 0.70%. Dividend treatment depends on the ETF structure and fund house policy.

Based on available data, Nippon India NIFTY Pharma ETF Growth Plan has delivered the following returns: 1-year return: 18.49%. 3-year return: 18.49%. 5-year return: 18.49%. Past performance does not guarantee future results.

Before investing in Nippon India NIFTY Pharma ETF Growth Plan, investors generally consider the underlying index, expense ratio, tracking error, risk profile, liquidity, and how the ETF fits within their overall portfolio strategy.